ClinicalTrials.gg
Not yet recruitingNCT06605963Updated Nov 2, 2026

PPV-06 Vaccine in Inflammatory Knee Osteoarthritis

A Phase 2 interventional study of PPV-06 and Placebo in Osteoarthritis, Knee, sponsored by Peptinov SAS. Not yet recruiting at 1 site in France. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Peptinov SAS · Phase 2, Interventional, and Treatment

How we know

Updated Nov 2, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 124 studies in Osteoarthritis, Knee with a site in France — 23 open to participants now, 33 under way, 1 of them phase 3. Osteoarthritis, Knee · France.

Planned enrollment
22nd of 86
204 · median 106
Started
2027
the only one that year
Phase 2
9 of 124
2 open now
Primary completion
2030-12
later than 29 of 32 live
Registered
107th of 124
by date

Among the 124 studies in Osteoarthritis, Knee with a site in France, this one is the 22nd largest by planned enrollment of the 86 interventional ones that give a count, is the only one that started in 2027, is one of 9 in phase 2, reaches primary completion later than 29 of the 32 other live ones, and was the 107th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

23 of the 124 studies in Osteoarthritis, Knee with a site in France are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Osteoarthritis, Knee with a site in France, or all of them as a file.
02

Study summary

PPV-06 targets interleukin-6, a key molecule implicated in many inflammatory diseases such osteoarthritis. PPV-06 is used to induce the production of antibodies directed against IL-6. The antibodies produced will neutralize the interleukine-6 involved in the body's inflammatory process.

The goal of this clinical trial is to test the safety and efficacy of PPV-06 in participants with Knee Osteoarthritis. The main questions are to evaluate if PPV-06 can reduce pain and improve functioning in participants with knee osteoarthritis, and to evaluate if ¨PPV-06 is safe when administered to participants.

Participants will be administered with 6 subcutaneous injections of either PPV-06 or placebo, over a two-year period.

Read the detailed description

This study assesses the safety and efficacy of PPV-06 active immunotherapy versus placebo in patients who have inflammatory osteoarthritis of the knee.

PPV-06 active immunotherapy will be assessed at a dose level of 10 µg. In total, 204 patients will be randomized to receive either IMP or placebo in a ratio 1:1.

Patients will each receive 6 injections of IMP or a placebo during the Double-blind Treatment Period of 104 weeks. For each SC injection, patients will receive the same IMP or Placebo that was administered at the first injection, in a double-blind manner.

The study comprises a total of 13 scheduled on site visits and 5 scheduled phone calls, which are considered appropriate to collect trial data, monitor patients' safety, and support patients' compliance to meet trial objectives.

The overall study duration by patient will be approximately 108 weeks (up to 4 weeks for screening visit and 104 weeks of study treatment). The study comprises:

  • Screening period - V1 (up to - 28 days);
  • Treatment induction immune response period - V2 (D1), V3 (W4), V4;
  • Maintenance immune response period - V5 (W24), V6, V7 (W44), V8, V9 (W64), V10, V11 (W84), V12 ;
  • Phone calls between each scheduled visits as per protocol (PC1, PC2, PC3, PC4, PC5);
  • End of Study visit or Early Termination visit - V13 (W104).

Efficacy evaluations, including pain and physical function assessments, MSK examinations, MRI with contrast, clinical laboratory tests and health related quality of life (such as WOMAC, NRS, PGA, SF-36, EQ-5D-5L, PGIC, PSQI, PSFS, WPAI questionnaires by e-PRO and e-Diary) will be performed.

Safety evaluations, including physical examinations, vital signs, ECGs, X-Ray, Ultrasound (US), MRI with contrast, and clinical laboratory tests will be performed.

Concomitant medication usage will be recorded from the time of screening until the end of the study.

03

Conditions studied

  • Osteoarthritis, Knee

Keywords

  • Inflammatory osteoarthritis
  • Immunotherapy
  • Interleukine-6
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has given written to participate.
  • Male or female, aged at least 40 years old.
  • between 22 to 35kg/m² at Screening visit.
  • Diagnosis of osteoarthritis of the index knee based on American College of Rheumatology (ACR) criteria and functional capacity class of I-III, with a Kellgren-Lawrence grade [KLG] 2 or 3.
  • OARSI medial Joint Space Narrowing (mJSN) Grade 1 or 2 of the index knee joint, confirmed by a semi-flexed or fixed flexion weight-bearing X-Ray performed at Screening visit, and assessed by Central Reader.
  • Evidence during the Screening visit of synovitis in the index knee based on ultrasound as described in the Ultrasound Doppler manual.
  • Evidence of moderate to severe Synovitis on 11-point synovitis (based on Guermazi et al. score), as assessed by Rapid OA MRI Eligibility Score (ROAMES(1)), per-formed during the Screening visit and assessed by Central Reader.
  • Insufficient pain relief with standard of care (i.e. non-pharmacological treat-ments, systemic non-steroidal anti-inflammatory drugs (NSAIDs) and/or other analgesics) for symptomatic OA in the index knee within 6 months prior to the Screening vis-it.
  • Pain at index knee for the majority of days (>50%) during the preceding month prior to the Screening Visit.
  • At Screening Visit 1a, participant reports that their typical OA knee pain in one or both knees when not using medication is ≥ 4 out of 10.
  • WOMAC pain subscale score (5 items) in the range [≥4 and ≤8], using the 11-point (0-10) NRS for the index knee at Screening and Baseline visits.
  • Participant is willing to discontinue all pain medications for OA except rescue medication (pa-racetamol), to adhere to the restricted use of concomitant treatments and not use prohibited pain medications throughout the clinical trial.

Exclusion criteria

Exclusion Criteria:

  • Participant had an administration of NSAID (topical, tablets) or Cox-2 Inhibitors within 2 weeks prior to the Baseline visit.
  • Injection of either or intra-articular (IA) Visco-supplementation (i.e., hyaluronic acid) into the index knee within 1 month of Screening.
  • Injection of -rich plasma (PRP) into the index knee within 6 months of Screening.
  • Application of topical capsaicin on the index knee within 1 month of Screening.
  • Past joint replacement surgery of the index knee.
  • History of significant trauma or surgery (e.g., open or arthroscopic) to the in-dex knee within 12 months of Screening.
  • Scheduled surgery except dental surgery during the clinical trial period.
  • Any known active infection, including suspicion of intra-articular infection, ul-cer or open wound anywhere on the index knee.
  • Periarticular pain from any cause other than osteoarthritis, including referred pain, bursitis, tendinitis, soft tissue tenderness, or subacute/acute pain from injury in the index knee.
  • Known presence of pre-existing MRI-based findings warranting exclusion in accordance with the ROAMES criteria, such as rapidly progressing osteoarthritis (RPOA) Type I or Type II, osteonecrosis, subchondral insufficiency fracture, atrophic oste-oarthritis, severe bone on bone osteoarthritis, or knee pain attributable to disease other than osteoarthritis, or as assessed by X-Ray, based on Central imaging Reading at Screening Visit and before the Baseline Visit.
  • Significant malalignment of anatomical axis (medial angle formed by the femur and tibia) of the index knee (varus >10°, valgus >10°) by X-Ray as assessed by Central Readers at Screening Visit.
  • Other conditions that could affect trial endpoint assessments of the index knee, including, but not limited to, rheumatoid arthritis, psoriatic arthritis, ankylosing spondyli-tis, gout or pseudogout, inflammatory bowel disease related arthropathy, peripheral neuropathy, lupus erythematosus, significant skin conditions such as abscesses, acromegaly, metabolic joint diseases and fibromyalgia.
  • Neuropathic pain as assessed by PainDETECT questionnaire with a score of at least 18 at Screening Visit.
  • Systemic (except inhaled) agent within 6 months prior to trial medication administration.
  • Current disease(s) or condition(s) (including clinically significant cardiovascular disease and/or significant pain in other areas) that may affect efficacy or safety assessments, or any other reason which, in the investigator's opinion, may preclude the patient's participation in the full duration of the trial.
  • Major bleeding disorder encompassing, but not limited to coagulopathy and any current antithrombotic and anticoagulant events.
  • History of severe allergic or anaphylactic reactions.
  • Known infection of (HIV), or known current acute or chronic or C infection.
  • Unstable or poorly controlled blood pressure which, in the opinion of the inves-tigator, would put the patient at risk of severe adverse blood pressure increases upon IMP administration.
  • History of within 5 years prior to the Screening visit, with the ex-ception of basal cell carcinoma.
  • History of either active TB or latent TB with inadequate course of anti-tuberculous prophylaxis.
  • to an MRI (including the gadolinium contrast with a Glo-merular Filtration Rate () below 60 mL/min) of the index knee or has a pacemaker or any other implanted electronic devices. Claustrophobic patient with impossibility to under-go an MRI.
  • Evidence or history of severe psychiatric illness/disorder during 3 years prior to the Screening Visit that, in the investigator's opinion, may affect safety or efficacy assess-ments or may compromise the patient's safety during trial participation.
  • Known or suspected of not being able to comply with the requirements of the trial protocol or the instructions of the trial site staff.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
204 participants (estimated)

Study arms

  • Experimental
    PPV-06

    PPV-06 10 μg + Montanide™ ISA 51 VG in subcutaneous administration

    Drug: PPV-06

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugPPV-06

    6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84

  • DrugPlacebo

    6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of PPV-06 on pain in participants with knee Osteoarthritis

    Absolute change from baseline to Week 54 of the pain subscale score of the Western Ontario and McMaster University scale (WOMAC)

    Time frame: From Baseline to Week 54

  2. To evaluate the efficacy of PPV-06 on physical functioning in participants with knee Osteoarthritis

    Absolute change from baseline to Week 54 of the Western Ontario and McMaster University (WOMAC) physical function subscale score

    Time frame: From Baseline to Week 54

Secondary outcomes

  1. To evaluate the efficacy of PPV-06 on key structural features of knee Osteoarthritis

    Absolute change from baseline in cartilage thickness (ThC) in the medial femorotibial compartment (MFTC)

    Time frame: From Baseline to Week 104

  2. Cartilage thickness

    Absolute change from baseline in cartilage thickness (ThC) assessed by MRI at 1 and 2 years (W54 and W104) using quantitative image analysis method

    Time frame: From Baseline to Week 104

  3. Safety and Tolerability of PPV-06

    Incidence of Adverse Events of Special Interest (AESI).

    Time frame: From Baseline to Week 104

  4. To evaluate the efficacy of PPV-06 on key inflammation features of knee Osteoarthritis

    Absolute Change from baseline to Week 54 of Synovitis based on Rapid OsteoArthritis MRI Eligibility Score (ROAMES) 11-point synovitis score

    Time frame: From Baseline to Week 54

  5. Western Ontario and McMaster University total score

    Absolute Change of the Western Ontario and McMaster University (WOMAC) total score

    Time frame: From baseline to Week 54

Other outcomes

  1. Immune response and development of antibodies to treatment with PPV-06

    Change from baseline in inflammatory markers in serum (Il-6, hsCRP, CRPM)

    Time frame: From Baseline to Week 104

07

Study locations

1 site
  • CIC Cochin
    Paris, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2027; primary completion for Dec 2030, 44 months later.

Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's planned 44 months is above that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Dec 2025 → Apr 2027, primary completion Dec 2028 → Dec 2030 and completion Dec 2028 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2024
First posted
Sep 20, 2024
StartEst.
Apr 2027was Dec 2025
Primary completionEst.
Dec 2030was Dec 2028
CompletionEst.
Dec 2030was Dec 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Dec 2025→Apr 2027
Nov 2, 2026
Primary completion
Dec 2028→Dec 2030
Nov 2, 2026
Study completion
Dec 2028→Dec 2030
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Start date Dec 2025→Apr 2027
    Primary completion Dec 2028→Dec 2030
    Study completion Dec 2028→Dec 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06605963
Lead sponsor
Peptinov SAS
Responsible party
Sponsor
First posted
Sep 20, 2024
Start date
Apr 2027 (estimated)
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion